Kennedy Capital Management, Inc. Black Diamond Therapeutics, Inc. Transaction History
Kennedy Capital Management, Inc.
- $4.27 Billion
- Q3 2024
A detailed history of Kennedy Capital Management, Inc. transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Kennedy Capital Management, Inc. holds 657,036 shares of BDTX stock, worth $1.8 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
657,036
Previous 703,283
6.58%
Holding current value
$1.8 Million
Previous $3.28 Million
12.79%
% of portfolio
0.07%
Previous 0.08%
Shares
6 transactions
Others Institutions Holding BDTX
# of Institutions
114Shares Held
48.8MCall Options Held
1.8MPut Options Held
1.86M-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.7MShares$29.4 Million0.03% of portfolio
-
Bellevue Group Ag Kuesnacht, V88.52MShares$23.3 Million0.62% of portfolio
-
Vestal Point Capital, LP New York, NY5.03MShares$13.8 Million1.66% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$12.2 Million1.48% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$8.81 Million0.0% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $99.6M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...